AHB-137 is cleared for initiation of a clinical trial in CHB patients in the US AHB-137 is an unconjugated antisense oligonucleotide (ASO) aimed for functional cure of CHB SAN FRANCISCO, Aug. 25, 2023 /PRNewswire/ — AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (Together…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.